Low-Dose Naltrexone Non-Responder Profile: Who Doesn't Benefit and Why

Is there a published non-responder profile?

A 2026 narrative review screened 105 studies of low-dose naltrexone, 15 of them randomised trials, covering chronic pain, autoimmune and neuroimmune disease, gut disease, skin disease, post-infectious syndromes, mental health and oncology. It found that early positive results from uncontrolled studies were rarely confirmed in placebo-controlled trials, and that current evidence does not support routine clinical use [3].

The same review describes the usual 4.5 mg dose as empirically derived rather than evidence-based, and says larger trials with objective endpoints, along with N-of-1 approaches to identify potential responders, are needed [3].

Who genuinely cannot take LDN

Opioid medicines are the one clear-cut group. The naltrexone labels state that naltrexone hydrochloride tablets and Vivitrol are contraindicated in patients receiving opioid analgesics, in patients currently dependent on opioids including those maintained on methadone or buprenorphine, and in anyone in acute opioid withdrawal or with a positive urine screen for opioids [1][6]. Naltrexone is a pure opioid antagonist that blocks opioid effects by competitive binding at opioid receptors, and the tablet label records that 50 mg blocked the effects of 25 mg of intravenous heroin for up to 24 hours [1].

The tablet label recommends a minimum of 7 to 10 opioid-free days before starting, and says people switching from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [1]. Precipitated withdrawal can be severe: in the tablet label, symptoms usually appeared within 5 minutes of ingestion and lasted up to 48 hours, and postmarketing cases required hospital admission and sometimes intensive care [1].

The labels were written for the 50 mg tablet and the 380 mg injection. They give no guidance on LDN doses, and the opioid contraindication is written without any dose exception [1][3]. The tablet label also says patients taking naltrexone may not benefit from opioid-containing cough, cold and antidiarrheal medicines [1]. Contrave, the approved naltrexone-bupropion weight-management tablet, also contains naltrexone, and its label says coadministration with other naltrexone-containing products is not recommended [7].

Who did not benefit in the trials

Fibromyalgia is where LDN has been tested most often, and the results have moved against it. A 2013 crossover trial of 31 women found daily pain fell 28.8% on 4.5 mg naltrexone versus 18.0% on placebo (P=0.016), with 32% meeting a responder definition versus 11% on placebo (P=0.05); fatigue and sleep did not improve [8]. Even in that positive trial, most participants did not meet the responder definition while taking LDN [8].

The larger trials did not reproduce the result. In a Danish trial of 99 women, 12 weeks of 6 mg naltrexone lowered pain by 1.3 points versus 0.9 on placebo, a between-group difference of -0.34 (95% CI -0.95 to 0.27, p=0.27) [2]. A crossover study of 58 patients reported a median FIQR difference of -1.65 (P=0.3) and a summed pain rating difference of -0.33 (P=0.4), and the authors concluded the data did not indicate clinically relevant analgesic efficacy [9]. The 12-month INNOVA trial of 98 women found pain changes of -0.33 on LDN and -0.64 on placebo at 3 months, an adjusted difference of 0.49 (p=0.236) [10].

A 2024 meta-analysis of 4 randomised trials and 222 patients did find lower pain scores with LDN (mean difference -0.86, 95% CI -1.20 to -0.51) but no significant difference on the FIQR, and the pooled trials were small [11].

Crohn's disease has one small positive randomised trial. Forty adults with active disease took 4.5 mg daily for 12 weeks: 88% had at least a 70-point fall in CDAI versus 40% on placebo (p=0.009), 78% versus 28% had an endoscopic response (p=0.008), and 33% versus 8% reached endoscopic remission [5]. A separate open-label study of 47 people with inflammatory bowel disease reported clinical improvement in 74.5% and remission in 25.5%, but had no placebo comparison [12].

Conditions where evidence remains limited or uncertain

Long COVID has been studied only without controls. A systematic review searching to May 2026 identified no randomised trial; the evidence was four uncontrolled before-and-after studies of 155 people taking 1 to 6 mg a day, which reported improvements in fatigue, brain fog, sleep and pain but cannot separate a drug effect from placebo or the passage of time [13].

In multiple sclerosis the record is a single-centre pilot: 80 people enrolled and 60 completed, 8 weeks of 4.5 mg nightly, with improvement on mental-health quality-of-life scales including a 3.3-point gain on the SF-36 Mental Component Summary (p=0.04). The outcomes were self-reported quality of life, and the authors reported that dropout and data errors substantially reduced the trial's statistical power [14].

Compounded status

LDN is not FDA-approved. FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed, and that poor compounding practices can produce a drug with too much or too little active ingredient [3][4]. A 2026 review notes that inconsistencies in compounded formulations add further uncertainty to LDN evidence [3].

What the label flags

In LDN trials the reported effects are mostly mild and transient, most often insomnia, vivid dreams, nausea and dizziness [3]. A meta-analysis found more vivid dreams and nausea with LDN than placebo but no significant difference in serious adverse events [11].

The approved naltrexone labels, written for their own doses, report cases of hepatitis and clinically significant liver dysfunction, and the tablet label describes hepatocellular injury in placebo-controlled studies with up to 300 mg a day, five times the recommended 50 mg dose [1][6]. The Vivitrol label says to discontinue it for symptoms or signs of acute hepatitis [6]. Neither the current tablet label nor the Vivitrol label carries a boxed warning [1][6]. The naltrexone product that does is Contrave, whose boxed warning is for suicidal thoughts and behaviours from the bupropion component [7].